Vallerie's mailing address filed with the SEC is 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121.
Over the last 4 years, insiders at Clene Nanomedicine have traded over 1,293,164$ worth of Clene Nanomedicine stock and bought 19,236,803 units worth 21,152,263$ . The most active insiders traders include David J Matlin、Chidozie Ugwumba、Alison Mosca. On average, Clene Nanomedicine executives and independent directors trade stock every 26 days with the average trade being worth of 2,786,272$. The most recent stock trade was executed by Robert Dee Etherington on 29 July 2024, trading 27,320 units of CLNN stock currently worth 81,960$.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean surfaced nanotechnology (CSN) therapeutics. The company has a nanotechnology drug suspension; and engages in the development and commercialization of dietary supplements. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2 study for the treatment of stable multiple sclerosis; a Phase 2 biomarker study in Parkinson's; and Phase 2 and Phase 3 trials to investigate the potential for disease modification for neurodegenerative diseases. The company's products also include CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat disease-causing infections, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. Clene Inc. is headquartered in Salt Lake City, Utah.
Clene Nanomedicine executives and other stock owners filed with the SEC include: